tetano
Editor, Senior Moderator
Obes Sci Pract
. 2020 Dec 16;7(2):239-243.
doi: 10.1002/osp4.472. eCollection 2021 Apr.
Serum levels of ACE2 are higher in patients with obesity and diabetes
Valur Emilsson[SUP] 1 2 [/SUP], Elias F Gudmundsson[SUP] 1 [/SUP], Thor Aspelund[SUP] 1 [/SUP], Brynjolfur G Jonsson[SUP] 1 [/SUP], Alexander Gudjonsson[SUP] 1 [/SUP], Lenore J Launer[SUP] 3 [/SUP], John R Lamb[SUP] 4 [/SUP], Valborg Gudmundsdottir[SUP] 1 2 [/SUP], Lori L Jennings[SUP] 5 [/SUP], Vilmundur Gudnason[SUP] 1 2 [/SUP]
Affiliations
Abstract
Objective: As severity of outcome in COVID-19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were examined in these high-risk groups.
Methods: Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjav?k Study (AGES-RS) of the elderly (mean age 75 ? 6 years), using multiple linear regression analysis.
Results: Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups.
Conclusion: ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.
. 2020 Dec 16;7(2):239-243.
doi: 10.1002/osp4.472. eCollection 2021 Apr.
Serum levels of ACE2 are higher in patients with obesity and diabetes
Valur Emilsson[SUP] 1 2 [/SUP], Elias F Gudmundsson[SUP] 1 [/SUP], Thor Aspelund[SUP] 1 [/SUP], Brynjolfur G Jonsson[SUP] 1 [/SUP], Alexander Gudjonsson[SUP] 1 [/SUP], Lenore J Launer[SUP] 3 [/SUP], John R Lamb[SUP] 4 [/SUP], Valborg Gudmundsdottir[SUP] 1 2 [/SUP], Lori L Jennings[SUP] 5 [/SUP], Vilmundur Gudnason[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33841894
- PMCID: PMC8019273
- DOI: 10.1002/osp4.472
Abstract
Objective: As severity of outcome in COVID-19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were examined in these high-risk groups.
Methods: Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjav?k Study (AGES-RS) of the elderly (mean age 75 ? 6 years), using multiple linear regression analysis.
Results: Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups.
Conclusion: ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.